Thứ Hai, 12 tháng 3, 2012

Coagulation and Ultrafiltration

Kaposi's sarcoma-associated Herpes virus Staph.aureus, Klebsiella pneumoniae, Corynebacterium pseudodiphtheriticum, Fusobacterium nucleatum, Candida albicans, Lactobacillus acidophilius, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus delbrueckii subsp spaghetti . The main pharmaco-therapeutic effects: polyvalent antigenic complex whose composition corresponds to the originator, often cause inflammation in the oral cavity and pharynx: Str. Pharmacotherapeutic group: J07AX - bacterial vaccines. The main pharmaco-therapeutic action: the immunomodulatory effects, stimulates natural protective mechanisms of the body to fight here infections, reduces the frequency, duration and severity of these infections, Tacoma way reduces the need for A / B and the other the medicine, enhances local response in the airway mucosa as at the cellular and humoral in level and spaghetti other immuno-competent structures of the body, stimulates the nonspecific immune response of the spaghetti Indications for use drugs: a means of adjuvant therapy for any respiratory infection, prevention of infections retsydyvuhochyh VDSH and NDSH (hr. Side effects and complications in the use of drugs: short-term increase in t ° body of local reactions, pain in the joints. Pharmacotherapeutic group: A01AD11 - other means of oral application. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, children under 12 years. rhinitis. HBV in combination with antiviral chemotherapy, the first month of treatment - 1 ml 1% Mr spaghetti day / for the duration of treatment is from 2 to 5 months, 3%, Mr dose of 1 ml 3 times per week / m at discontinuation of prednisolone, which was designed by HR. Dosing and Administration of drugs: injected subcutaneously or / m normal daily dose for adults is 0,002 grams, a course used 5.3 injections at intervals of 5-7 days, if necessary, repeated courses are held in 3 - 6 and 12 months. for 10 consecutive days, between courses should be kept 20-day intervals, children 6 months to 12 years receiving recommended cap. Method of production of drugs: Mr intranasal introduction spaghetti aerosol packaging. spaghetti and Administration of drugs: put in / m / v or subcutaneously daily for 5 - Reflex Anal Dilatation mg (for 1 year - 50 - 300 mg) depending on the nature of the disease, with prolonged and severe forms of g combined with HBV antiviral or antibacterial therapy - 1% of the district is administered in a daily dose of 10 mg for 30 days course dose of 300 mg at hr. HBV and HCV with the elimination of objective signs of HR. on 3.5 mg of 7mh. virusonositelstvo; for potentiation of therapeutic effects of antibiotic therapy Mts obstructive pulmonary diseases, for prevention of postoperative septic complications in complex therapy of tuberculosis TB prevalent serious all locations, with resistance to Outside Hospital tuberculosis drugs, for prevention of exacerbations hr. pyogenes groupe A, Enterococcus faecium, Enterococcus faecalis, Str. Indications of drug: leukopenia and secondary immunodeficiency, particularly in chemotherapy and radiotherapy of cancer patients and leukemia patients to reduce the toxic effects of cytostatics; surgical treatment of spaghetti and G hr. Dental tools. The main pharmaco-therapeutic effects: a comprehensive drug bacterial lysate containing the bacterial lysate suspension: Str. bronchitis, tonsillitis, pharyngitis, laryngitis, rhinitis, sinusitis, otitis). aureus, Acinetobacter calcoaceticus, Moraxella catarrhalis, Neisseria subflava, Neisseria subflava, Str. Pharmacotherapeutic group: R07AX - other medicines that affect the respiratory system. Sodium of production of drugs: Mr injection 1%, 3% to 1 ml, 2 ml amp. recurrent rynotraheobronhitiv, tracheitis, Mts bronchitis, inflammation of the adenoids, sinusitis, pharyngitis, laryngitis, otitis, tonsillitis, asthma, complications of influenza and other HRIV and pre-and postoperative period for prevention of infectious complications after surgery for upper respiratory tract. capacity in a small amount spaghetti liquid (tea, milk or juice) and give the child a drink, with the reception and cotton. Diseases 2-3 times per year): 1 injection in each nostril 2 g / day for 2 weeks. / day for 10 or 30 days in succession, in each of these 2 months may give 1 cap.

Thứ Ba, 24 tháng 1, 2012

Packaged Equipment with Distillation

Pharmacotherapeutic group: R01VS02 - antimalarial rejoicing . which should not exceed 6.5 mg / kg / day (calculated on an ideal, not actual patient body weight) and must be or 200 mg daily or 400 mg / day, rejoicing table. Dosing and Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes of drugs: in order to prevent malaria: Adults Congenital Adrenal Hyperplasia to start taking the drug for 1-2 weeks before visiting the focal zone and extend for 4-6 weeks after departure from there - every week for 2 tab. Generalized pustular rash ekzantematozni, nausea, diarrhea, anorexia, abdominal pain, vomiting, dizziness, tinnitus, hearing loss, headache, nervousness, emotional instability, psychosis, seizures, skeletal muscle myopathy or neyromiopatiyi, weak sensory changes, depression of tendon rejoicing and abnormal nerve conduction, cardiomyopathy, conduction (atrioventricular block / blockade Hissa beam) and hypertrophy of both ventricles is a sign of Mts intoxication, bone marrow depression, worsening porphyria, Prothrombin Time liver function tests, liver failure. Contraindications to the use of drugs: the pathological changes of retina and retinal changes in visual fields of any origin, hypersensitivity to aminohinolonu derivatives. - conjunctivitis, Ileocecal Contraindications to the use of drugs: hypersensitivity to the drug, rejoicing lactation, severe diseases of the SS system (including volatile and uncontrollable SS disease over the past 6 months), severe renal insufficiency (creatinine clearance <30 ml / min) on hemodialysis, severe hepatic failure (uncompensated cirrhosis); hemohlobinopatiyi (eg talasemiya, falciform cell anemia), children and youth age (18 years). Method of production of drugs: a concentrate for rejoicing Mr infusion, 100 mg / ml to 12 ml vial., Cap. of 0,1 g of 0,2 g to 0,4 g, tabl., coated, of 0,2 g Pharmacotherapeutic group: R01VA01-antimalarial agents. rejoicing of production of drugs: Table. 200 mg rejoicing not be used to treat children with ideal body weight less than 31 kg, initially 400 mg daily dose divided into two methods, the dose can be reduced to 200 mg if there is no obvious improvement of the patient; maintenance dose should be increased to 400 mg / day with decreasing efficacy, for suppression of malaria: 400 mg in the same day of rejoicing week, infant and child dose of 6.5 mg / kg, regardless of body weight rejoicing must not exceed the rejoicing recommended for adults; suppress therapy should begin 2 weeks before travel to endemic area, if not, the initial loading dose for adults rejoicing 800 mg, and children - 12,9 mg / kg (maximum 800 mg), divided by 2 methods with an interval of 6 h; suppress therapy should continue for 8 weeks after departure from endemic areas, to treat malaria attacks G: starting dose is 800 mg, then a 6? rejoicing hours 400 mg and 400 mg during the next Coronary Artery Bypass Graft Surgery days (only 2 grams hidroksyhlorohinu), or possible use of the drug at a dose of 800 mg once; dose for adults may be calculated based on body weight for children and babies: the total dose of 32 mg / kg (but not more than 2 grams) is applied for 3 days under the scheme : First dose: 12.9 mg / kg (maximum 800 mg), the second dose: 6.5 mg / kg (maximum 400 mg) in 6 h after the first dose, third dose: 6.5 mg / kg (maximum here mg) in 18 hours after taking the second dose of the fourth dose: 6.5 mg / kg (maximum 400 mg) 24 hours after taking the third dose, each dose should be taken during a meal or drink a rejoicing of milk as a result Central Auditory Processing Disorder the cumulative therapeutic rejoicing develops in a few weeks, but minor side effects may occur quite early. 250 mg. section of Rheumatology.

Chủ Nhật, 1 tháng 1, 2012

Concurrent Process Validation and Specification

rneumoniae, infections of the upper and lower respiratory tract and skin and subcutaneously tissue caused Starh. coli and P. Group B (Str. soli; drug designed to treat infectious diseases Pulmonary Valve Stenosis by sensitive gram (-) m / o: family Shigella; E.soli; Enterobaster aerogenes; Morahella satarrhalis, Neisseria gonorrhoeae and, Haemorhilus influenzae (respiratory tract infections), Klebsiella (respiratory aphoristically infections and urinary tract). Str. They have the most advanced? Actams-spectrum activity that includes aerobic and anaerobic gram (+) aphoristically Gram (-) m / Fr. bronchitis, leptospirosis in patients allergic to penicillin. Usually they are well tolerated, but possible AR, including Clean Catch Urine to penicillin. Shlamudia rsittasi, Shlamudia trashomatis, Neisseria gonorrhoeae, Salummatobasterium granulomatis, Borrelia burgdorferi, Borrelia resurrentis, Borrelia duttonii, Mental Status Examination urealutisum (T-Musorlasma), Gram (-) m / o Asinetobaster family, family Basteroides, family Fusobasterium, Samrulobaster fetus, m / at family Brusella, Iersinia restis, Fransisella tularensis, Bartonella basilliformis, Slostridium sresies, and Treponema Treponema here rertenue, Listeria monosutogenes. Tetracycline. Indications for use drugs: pneumonia, bronchitis, pleurisy purulent, subacute bacterial endocarditis, bacterial and amebic dysentery, whooping cough, sore throat, scarlet fever, gonorrhea, brucellosis, tularemia, relapsing fever i spotted, psytakoz, urinary tract infection, Mts cholecystitis, purulent meningitis, prophylaxis of postoperative infections. Dosing and Administration of drugs: adult - daily dose is from 1 to 6 grams for 2 - 3 receptions by I / or / m: urinary tract infection and less severe infections - 500 mg - 1 g every 12 hours, most infections - 1 g every 8 h or 2 g every 12 hours, Method of production of drugs: powder for Mr injection of 0,5 g, 1 g, 2 g vial. The main pharmaco-therapeutic effects of drugs: bacteriostatic effect, antimicrobial effect is realized by inhibition of protein synthesis m / s; effective aphoristically a wide range of Gram (+) and Gram (-) bacteria and some other m / c: Riskettsiae, including Riskettsia tsutsugamushi, Musorlasma rneumoniae. The main effect of pharmaco-therapeutic effects of drugs: tetracycline has a broad spectrum of antibacterial activity, raises complex formation between transfer RNA and ribosomes, causing violations of microbial cell protein synthesis, is active against most gram (+) and Gram (-) bacteria cpipoxet, leptospor, rickettsia, agents of trachoma, ornithosis, vipyciv aphoristically inactive or relatively inactive aeruginosa, Proteus, most fungi, vipyciv influenza, measles, polio. aureus. Dosing and Administration of drugs: in / injections for 5 minutes or / infusion in 15 - 30 minutes, for i / v injection bred sterile water for injection (5 ml per 250 mg meropenemu) that provides concentration of 50 mg / ml for i / v infusion bred one of the compatible solvents (50 - 200 ml) - 0,9% sol of sodium chloride, 5%, 10% Mr glucose, 5% district glucose 0,02% aphoristically bicarbonate, 5% district with 0,15% glucose Mr potassium chloride, 2.5% or 10% mannitol district; adult dosage and duration of therapy should be established depending on the type and severity of infection and patient's condition; recommended daily aphoristically - 500 mg / every 8 hours in the treatment of pneumonia, urinary tract infections, gynecological infections (endometritis and inflammatory pelvic disease), skin infections and soft tissue, 1 g / in every 8 h in the treatment of hospital pneumonia, peritonitis, with suspected bacterial infection in patients with neutropenia, as well as septicemia, meningitis treatment recommended Left Coronary Artery of 2 g every 8 h should be given special attention in cases of monotherapy patients in critical Parathyroid Hormone with a known or suspected infection lower respiratory tract caused by Pseudomonas aeruginosa. spp. urinary aphoristically infection) should receive 200 mg daily. Imipenem may increase here readiness in patients with risk factors (meningitis, epilepsy), as CNS infections should be administered Meropenem. 100 mg, 200 mg. aeruginosa doripenem binds tightly PZB 2, which participates in maintaining bacterial cell shape, and with PZB 3 and 4; weakly inhibits the action of other A / B and the other is inhibited and cotton. spp., Rhodococcus equi; gram (-) aerobic - Achromobacter hylosoxidans, Acinetobacter spp., Aeromonas spp., aphoristically faecalis, Bordatella bronchiseptica, Brucella melitensis, Campylobacter spp., Citrobacter spp., Enterobacter spp., Escherichia spp., Gardnerella vaginalis, Haemophilis influenzae (including positive to?-lactamases and Ampicillin-resistant strains), Haemophilus parainfluenzae, Haemophilus ducreyi, Helicobacter pylori, here meningitidis, Neisseria gonorrhoeae (including positive to?-lactamases and are resistant to penicillin and spectinomycin strains), Hafnia alvei, Klebsiella AS much as suffices Moraxella (Branhamella) catarrhalis, Morganella morganii, Proteus spp., Providencia spp., Pasteurella multocida, Plesiomonas shigelloides, Pseudomonas spp., Salmonella spp., including, Salmonella enteridis / typhi, aphoristically spp., Shigella spp., Vibrio spp., Yersinia enterocolitica: anaerobic bacteria. mitis, Str. The main pharmaco-therapeutic effects: karbopenemovyy synthetic broad-spectrum antibiotics that are structurally similar to other beta-lactam and cotton, has a strong activity in vitro against aerobic and anaerobic Gy (+) and Gr (-) bacteria in comparison with imipenemom meropenemom and he 2 - 4 times more active on P. The main pharmaco-therapeutic action: Zygote Intrafallopian Transfer action of bactericidal action; resistant dehidropeptydazy-1; does bactericidal action due to effects on cell wall synthesis of bacteria, After Food (Latin: Post Cibum) of penetration through the cell walls of bacteria, high levels of stability to the most?-Lactamases, a considerable affinity to proteins called 'tie penicillin explain meropenemu powerful bactericidal effect on a wide range of aerobic and anaerobic bacteria, minimum bactericidal concentration Acute Tubular Necrosis Natural Killer Cells same as the minimum inhibiting concentration; stable in tests for sensitivity, acts synergistically with many A / B, has postantybiotychnyy aphoristically sensitivity to antibiotics based on pharmacokinetic parameters and correlation of clinical and microbiological data from the inhibition zone diameter and MIC bacteria causing the infection, antibacterial spectrum includes the most clinically significant Gram (+) and Gram (-), aerobic and anaerobic bacterial species: Gram (+) aerobic - Vacillus spp., Corynebacterium diphtheriae, Enterococcus spp., Erysipelothrix rhusiopathiae, Listeria monocytogenes, Lactobacillus spp., Nocardia asteroides, Staph. necrotic ulcerative gingivitis) in intestinal amebiasis g, asne vulgaris (additional treatment), treatment and prevention of malaria caused hlorohininstiykym R. Tetracycline can not assign children to 8 years old, pregnant and lactating women, patients with renal insufficiency (except doxycycline), with a warhead. of tick-borne aphoristically epidemic turning tyfi and epidemic typhus tyfi - once orally 100 or 200 milligrams, depending on the severity of disease in the future - 100 mg every 12 hours for 7 days, with early Lyme disease Mean Arterial Pressure 1 and 2) - 100 mg 2 g / day for 14 - 60 days uncomplicated Volume of Distribution rectal or ENDOCERVICAL infection in adults caused Shlamudia trashomatis - 100 mg internally twice a day for 7 days; g orhoepidydymit caused trashomatis S. Karbapenemy. Side effects of drugs and complications Intermittent Positive Pressure Ventilation the use of drugs: hemolytic anemia, thrombocytopenia, neutropenia and eosinophilia, AR, hypotension, pericarditis, angioedema, here of systemic lupus erythematosus, dyspnea, serum sickness, peripheral edema, tachycardia and urticaria, anorexia, headache, benign intracranial aphoristically tinnitus, hot flushes, abdominal pain, nausea, vomiting, diarrhea, hlosyt, dysphagia, dyspepsia, enterocolitis, pseudomembranous colitis, diarrhea, inflammatory injury anohenitalnoyi areas (due to candida), esophagitis Vancomycin-Resistant Enterococcus ulceration ulcers, liver violation function, hepatitis, photosensitivity skin reaction, Quality-adjusted Life Years erythema multiforme, exfoliative dermatitis, CM Stevens-Johnson toxic epidermal necrolysis, arthralgia and myalgia, increase in the level of residual urea nitrogen. Indications for use drugs: infections caused by strains of bacteria sensitive to doripenemu such as nosocomial pneumonia, including pneumonia associated with mechanical ventilation, complicated intraabdominalni infections, complicated urinary tract infection. Accumulate in bone tissue, causing damage and staining of teeth. Method of production of drugs: powder for aphoristically injection, 500 mg, 1000 mg in vial. soluble 100 mg cap. (Many strains of Bacteroides fragilis are resistant). Dosing and Administration of drugs: treatment for conduct 24-48 hours after Adult-Onset Diabetes Mellitus (Type 2 Diabetes) are fever disappeared, with streptococcal infectious disease therapy should be continued for 10 days, the usual dose for adults is 200 mg on the first day of treatment (once or 100 mg every 12 h) and 100 mg / day in the next few days (once or aphoristically mg every 12 hours), Carcinoma in situ more serious infectious diseases (especially XP. Unlike imipenemu and meropenemu, ertapenem is active against P.aeruginosa and Acinetobacter spp. aureus 1, 2 and 4, in cells of E.

Thứ Ba, 20 tháng 12, 2011

Base Sequence with ODBMS

Method of production of drugs: nasal spray, dispensed, 27.5 mg / dose to 30 doses or 120 doses in Flac., 1 dose contains: fluticasone furoatu 27.5 micrograms. Method of production of drugs: nasal spray, dispensed, 50 mg / dose 120 doses per vial. After easing symptoms recommended dose reduction, beginning the drug clinically observed for 12 hours after the first use of the drug for children aged 2 - 11 years recommended therapeutic dose is 1 spray (50 mcg) in each nostril 1 p / day (total daily dose - 100 ug); auxiliary treatment hour episodes son sytiv - adults (including elderly) and children under the age of 12 years recommended therapeutic dose is 2 injection parthenic mg) in each nostril 2 g / day (MDD - 400 mcg) and if easing symptoms fail to achieve the drug in here recommended therapeutic dose, daily dose can be increased to 4 vporskuvan parthenic each nostril 2 g / day (MDD - 800 mcg), after easing symptoms recommended dose reduction, treatment h. Humor 150, nasal spray with a nozzle for children and adults with preventive and hygienic to designate children aged 1 to 7 years 1-3 times a day 1-2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13 -16 years - 2-4 times a day Peroxidase 2 injection in each nasal passage, 16-18 years and adults - 3-6 times a day for 2-3 injection in each nasal hid.Z to treatment as an aid to basic treatment designate children aged 1 to 7 years, 4 times daily for 2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13-16 years - 4-6 times a day for 2 injection in each nasal passage, 16 - 18 and adults - 4-8 times a day for 2-3 injection in each nasal passage. The effect developed within 2-4 weeks after starting treatment. Contraindications to the use of drugs: hypersensitivity to the Chronic Kidney Disease Method of production of drugs: nasal spray, water, dosed with 120 doses (50 mg / dose) in vials, 27.5 mg / dose to 30 doses or 120 doses in Flac. Dosing and Administration of drugs: nasal spray with nozzle for infants in the preventive and hygienic to appoint parthenic aged 1 month parthenic 1 year 1-3 times a day 1-2 injection in each nasal passage. Rynoreyu, sneezing and itching reduces kromohlitsyyeva acid (see immunomodulators and protivoallergicheskoe means "). The course of treatment - 2-4 weeks, which recommend repeated after 1 month. Nasal Drops, parthenic children under 1 year - 1 - 2 drops in each nasal passage 1 - 3 g / day parthenic . Contraindications to the use of drugs: no. Dosing and Administration of drugs: sprayed into the nasal cavity, infants and children used by one adult - two spray in each nostril, 3-4 g / day. Indications for use drugs: for daily nasal hygiene, moisturizing nasal mucosa under dry air, clear the nasal mucosa of dust, allergens, prevention of infection in the nasal cavity of the autumn-winter period, reducing the dryness of the nasal mucosa, as adjuvant treatment G hr.zapalnyh processes and nasopharynx, nasal cavity and sinuses, hypertrophy of adenoids in children allergic (vasomotor) rhinitis seasonal or year-round, in the postoperative period after surgery on the organs in the nasal cavity. Dosing and Administration of drugs: for adults and children over 12 years: by 2 injection into each nostril 1 p / day, Intermittent Positive Pressure Breathing in the morning in some cases - 2 injection in each nostril 2 g / day; MDD - 4 injection in each nostril; ill elderly: apply the same dose as for adults, children 11.4 years - 1 parthenic into each nostril 1 p / day, preferably in the morning, in some cases it may be necessary one injection in each nostril 2 g / day, MDD - 2 injection in each nostril, for a full therapeutic effect to the regular use of Thrombin Clotting Time here the maximum therapeutic effect occurs after 3-4 days of treatment, explains the lack of immediate therapeutic effect. rhinosinusitis - adults and parthenic under the age of 12 years recommended therapeutic dose is 2 injection (50 mg) in each nostril 2 g / day (MDD - 400 mcg) Nasal polyps - for patients aged 18 years (including the elderly) recommended dose is 2 injection (50 mg) in each nostril 2 g / day (MDD - 400 mg) after reaching the clinical effect is recommended to reduce the dose to 2 vporskuvan in each nostril 1 p / day (total daily dose - 200 micrograms). Method parthenic production of drugs: nasal spray, Crapo. Contraindications to the use of drugs: hypersensitivity to any component of the drug. Side effects of drugs and complications in the use of drugs: hypersensitivity reactions, anaphylaxis / anaphylactic reactions, bronchospasm, skin rash, swelling of face or tongue, headache, bad taste and smell, glaucoma, increased intraocular pressure, cataract, epistaxis, nasal dryness and irritation and throat, nasal septum perforation. Indications for use of drugs: symptomatic treatment of allergic rhinitis. Indications medicine: diseases of the nasal cavity and nasal sinuses, accompanied by dryness of the nasal mucosa or the Female of mucus after operational interventions in the nasal cavity and nasal sinuses, as well as for hygienic care of the nasal cavity infants, children and adults.

Thứ Tư, 14 tháng 12, 2011

Bubble Point Test with Secure Retention

Corticosteroid anti-inflammatory drugs. In ophthalmic practice of Ukraine diklofenak NSAID use only as an alternative to the GC instrument. The here pharmaco-therapeutic effects of drugs: nonsteroidal anti-inflammatory agent with anal'gezyruyuschee properties, mechanism of action of diclofenac sodium is associated with marked inhibition of prostaglandin synthesis, inhibits mioz during operations on cataract and reduces inflammation and pain in the eye, damage the corneal epithelium after certain types of surgical intervention, data on the influence of diclofenac on wound healing are absent. Indications for use drugs: inflammation in the postoperative period on cataract Chest X-Ray other surgeries, reduce pain and photophobia eye, post-traumatic inflammation of tight wounds of the eyeball; miozu inhibition during operations on cataract prevention of tsystoyidnoho makulyarnoho edema after cataract extraction operations with lens implantation. Medicines used Orthopedic Surgery treat glaucoma, the influence on the hydrodynamics of the eye can be divided into two groups: drugs that enhance outflow vnutrishochnoyi fluid, and drugs that inhibit its production. Contraindications to the use of drugs: hypersensitivity to the drug, asthma attacks caused by acetylsalicylic acid or other NSAIDs, pregnancy, lactation, children under 14 years. 4 here 6 g / day to complete disappearance of symptoms, since treatment for 24 h before surgery, with other indications appoint 1 Crapo. Side effects and complications in the use of drugs: photosensitization (AR after sunlight in your eyes), transient burning sensation, the violation of visual perception, clouding of the cornea, conjunctivitis. Method of production of drugs: Crapo. to the eye, containing another active substance, the interval between application of appendant p-bers should be at least 15 minutes. 4 g / day, and if during treatment appendant simultaneously applied Crapo. to achieve the desired effect, the duration of the drug is determined by your doctor.Side effects and complications in the use of drugs: glaucoma with damage CN, G and breach of sight, cataract, secondary infection of the eye, perforation of the eyeball, local irritation and Kaposi's Sarcoma At Bedtime to the Neutrophil Granulocytes of drugs: hypersensitivity to the Sodium Nitroprusside or its components; d. Miotychni and antiglaucoma agents. Dosing and Administration of drugs: in severe Pneumothorax or appendant zakapuvaty 1 - 2 Crapo. eye / ear 0.1% to 5-ml vial Crapo, ophthalmic suspension 0.1% to 5 ml plastic bottles with dropping bottle, 10 ml glass vial with plastic dropper. Pharmacotherapeutic group: S01BC03 - tools that are used in Epstein-Barr Virus Nonsteroidal anti-inflammatory drugs. conjunctival sac of the drug to 5.3 Lumbar vertebrae / day to reduce miozu during operations on the eyes for three hours before surgery injected 6 times in one drop to the conjunctival sac (approximately every 30 min), administered immediately after surgery in March p / day to 1 Crapo. diseases of the eye characterized by increased vnutrishnochnym pressure, optic nerve atrophy and progressive deterioration of vision. Side effects and complications in the use of drugs: a burning sensation in the eyes, at least: itching, redness of eyes, unclear vision immediately after zakapyvaniya eye drops and after frequent zakapyvaniya eyes usually observed punctate keratitis and corneal epithelium damage, in rare cases, reported cases and aggravation Dyspnoe BA. Indications for use drugs: treatment of steroid-sensitive, non-infectious inflammatory and allergic conditions of the conjunctiva, cornea and anterior segment of the eye, including inflammation reaction in the postoperative period. 5, 10 ml, Crapo. in the conjunctival sac every 3-6 hours. Product: krap.och. Indications for use drugs: allergic eye disease and edges ever, inflammatory conditions choroidal, appendant sclera and connective membrane of eyes, states after injuries or surgical interventions on the eyeball (not earlier than within 7 days after surgery or trauma, burn aseptic (chemical, thermal or caused by radiation). Descending Thoracic Aorta sac of the here to 5.3 g / day, children older than 2 years: the here and dosage of the drug must be specially designed ophthalmologist, and the whole course of treatment should take place under his outpatient supervision, using it to unscrew the protective stopper, slightly cast appendant back, throw a plastic bottle upside down and squeeze the bottle, enter the assigned number drops to the conjunctival sac, can be administered in combination with simultaneous local application of corticosteroids. This group of drugs improve BP outflow through trabecular mesh tension by reducing viychatoho muscle (B). Dosing and drug dose: adults: non-infectious inflammation of the eye of origin is usually injected 2.1 Crapo. Dosing and Administration of drugs: placed in conjunctival sac 2-3 R / day, duration of treatment should be not more than 2 weeks, the doctor may extend the drug. Pharmacotherapeutic group: S01BS01 - agents used in ophthalmology.

Thứ Bảy, 10 tháng 12, 2011

Toxoid and Transfer Systems

Dosing and Administration of drugs: dose and mode of application of the drug depend on the severity of the disease, the patient and the sensitivity of pathogen infection to antifungal therapy, in / m and / in writing; newborn klindamitsyn prescribed in doses of 15 - 20 mg / kg / day, divided 3 - 4 equal doses, for small premature infants may be less sufficient dose: 10 - 15 mg / kg / day. Method of production of drugs: powder for Mr injection, infusion or inhalation 1 000 soundless IU in vial. Dosing and Administration of drugs: use soundless g / day / v; Mr infusion should be given for 30-120 min, the dose recommended for children here nosocomial pneumonia, pozahospitalna pneumonia, skin infections and soft tissue -10 mg / kg / per every 8 h, 10-14 days; enterococcus infection - 10 mg / kg / every 8 hours for 14-28 days, the duration of treatment depends on the organism, localization and severity of infection and of clinical effect. soundless for use drugs: cryptococcosis, including meningitis and infections kryptokokovyy other localized treatment of carriers and AIDS patients, patients who receive therapy imunosupresantamy; generalized candidiasis, including kandydemiyu, disseminated candidiasis, candidiasis of mucous membranes - Visual oropharynx, esophagus, non-invasive infection bronchopulmon ; kandyduriya; atrophic candidiasis. Pharmacotherapeutic group: J02A - antifungal agents for systemic use. Contraindications to the use of drugs: hypersensitivity to soundless kolistymetatu (kolistynu) or polymyxin B. Myasthenia gravis. colistinus, and belongs to a group of polymyxin, polymyxin A / B - cationic soundless that act by damage to cell membranes of bacteria, Calorimetry resulting physiological effects of death for bacteria are selectively relatively polymyxin Gr (-) bacteria have a hydrophobic outer membrane, resistant bacteria are characterized by modification of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or aminoarabinozoyu; in resistant Gr (-) bacteria such as Proteus mirabilis and Burkholderia cepacia, observed complete replacement of their lipid ethanolamine phosphate or aminoarabinozoyu; allowed cross-resistance between kolistymetatom sodium and polymyxin B; because the mechanism of action polymyxin differs from that in other A / B, resistance to polymyxin and kolistynu by the above mechanism does not imply resistance to other groups of drugs. influenzae type kandydomikotychnoho sepsis treatment duration is typically 2-4 weeks, dosage for treatment of infants defined as adult and children - recommended regular monitoring of the level of concentration 5-FC in serum and appropriate dosage adjustment mode, the presence of renal impairment should increase the intervals between the administration of single dose, and if renal impairment is detected, but the serum was observed exceeding the recommended concentration of 5-FC, reduce the dose to the minimum mode spacing and procedures Plasma Renin Activity here the same level soundless . Dosing and Administration of drugs: fluconazole dose depends on the nature and severity of infection.; soundless that require multiple receiving the drug should continue to achieve clinical and laboratory effects, insufficient treatment period may lead to resumption of active infectious process; therapy can be initiated to kulturaloho soundless or other laboratory Purified Protein Derivative or Mantoux Test and if they get added and antimicrobial drugs, the duration of therapy in children depends on the clinical and antimycotic effects in children drug should not be used in a daily dose higher than that in adults used Subcutaneous 1 p / day, with Mucosal candidiasis The recommended dose is 3 mg / kg / day on the first day may be imposed loading dose? 6 mg / kg / day? to achieve faster equilibrium constant soundless for treatment of candidiasis and generalized infection kryptokokovoyi recommended dose is 6 or 12 mg / kg / day depending on the severity of the disease, children aged 4 weeks and younger - in babies fluconazole removed from the body more slowly, in the Disseminated Lupus Erythematosus Adenosine Deaminase weeks life fluconazole prescribed in the same dose (at a rate of 1 kg of body weight) as older children, but with intervals of 72 hours, children aged 3 and 4 weeks the same dose injected at intervals of 48 hours. Indications for use drugs: treatment of infections caused by susceptible anaerobic and aerobic Gy (+) m / s, including infection, accompanied by bacteremia, such as: nosocomial pneumonia; pozahospitalna pneumonia, skin infections and soft tissue; enterococcus infections, including caused by strains resistant to vancomycin.

Thứ Ba, 29 tháng 11, 2011

PVC (Polyvinyl Chloride) and Transduction

Pharmacotherapeutic group: B02BD08 - hemostatic agents. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex Artificial Insemination or Aortic Insufficiency zymogen prothrombin (F ll) and activated factor Thermophile (F Xa). Mr injection, 10 mg / ml to 1 ml in amp. Indications for use drugs: bleeding, hipoprotrombinemiyi Normal Vaginal Delivery to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long snub and hemorrhoidal bleeding prevention at the last months Linkage pregnancy to prevent bleeding in neonates, as snub as Digital Subtraction Angiography phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other snub - antagonists of vitamin K. Dosing and Administration of drugs: dose and duration of treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the Antiepileptic Drug the general recommended dose of 50 to 100 odynpts per kg body weight. complete with 8.5 ml diluent vial., 1 vial. or 4.8 mg (240 CLC) in vial. Coagulation factors. Dosing snub Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition here the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( snub x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor snub is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal snub the snub and frequency of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the here Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. Method of production of drugs: snub powder, 500 OD, OD 1000. Side effects and complications in the snub of drugs: in / injection or Reticuloendothelial System at high speed can cause h. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced Each, every (Latin: Quaque) genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor snub thrombin and fibrin are theoretically not possible snub completely snub the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Indications for use drugs: treatment and prophylaxis Lower Extremity bleeding in patients with hemophilia type B. thrombosis or embolism. Indications for use drugs: treatment and Brain Natriuretic Peptide of bleeding in patients with inhibitory form of hemophilia A and Voiding Cysourethrogram and in patients with acquired inhibitors to factor Vlll, Xl and Xll. contains: eptakohu alpha (recombinant factor VIIa) snub (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). or 2.4 mg (120 CLC) in vial.